

Caplin Point Laboratories Limited

Regd. office: Ashvich Tower, 3rd Floor, No.3, Developed Plots Industrial Estate, Perungudi, Chennai – 600096.
Phone: +91 44 24968000 / +91 80127 72888 / +91 44 71148000
E-mail: info@caplinpoint.net / Website: www.caplinpoint.net

CIN: L24231TN1990PLC019053

September 20, 2023

BSE Limited

Department of Corporate Relationship 1st Floor, New Trade Ring, Rotunda Building Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 *Scrip Code: 524742*

National Stock Exchange of India Ltd

Department of Corporate Services Exchange Plaza, 5th Floor, C-1, Block G,Bandra Kurla Complex, Bandra (E),Mumbai – 400 051 Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

<u>Sub: Press Release - Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</u>

Attaching herewith a Press Release regarding grant of final approval by the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Norepinephrine Bitartrate Injection USP, to our Subsidiary Caplin Steriles Limited. Request you to take the same on record.

Thanking You,

Sincerely Yours
For Caplin Point Laboratories Limited

Venkatram G
General Counsel & Company Secretary
Membership No. A23989
Encl: A/a